These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10830407)

  • 1. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions.
    Siderowf AD; Holloway RG; Stern MB
    Mov Disord; 2000 May; 15(3):439-45. PubMed ID: 10830407
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cost and quality aspects in the treatment of Parkinson's disease].
    Müller T; Dodel R; Fritze J
    Z Arztl Fortbild Qualitatssich; 2006; 100(4):291-5. PubMed ID: 16878798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease.
    Dams J; Siebert U; Bornschein B; Volkmann J; Deuschl G; Oertel WH; Dodel R; Reese JP
    Mov Disord; 2013 Jun; 28(6):763-71. PubMed ID: 23576266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study.
    Zhu XL; Chan DT; Lau CK; Poon WS; Mok VC; Chan AY; Wong LK; Yeung JH; Leung MC; Tang VY; Wong RK; Yeung C
    World Neurosurg; 2014 Dec; 82(6):987-93. PubMed ID: 25175275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: 'The cost of a QALY'.
    Adam J; Stevens A
    QJM; 2011 Mar; 104(3):272-3. PubMed ID: 21030464
    [No Abstract]   [Full Text] [Related]  

  • 8. Nursing and multidisciplinary interventions for Parkinson's disease: what is the evidence?
    Hagell P
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S501-8. PubMed ID: 18267291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement.
    Hjelmgren J; Ghatnekar O; Reimer J; Grabowski M; Lindvall O; Persson U; Hagell P
    Parkinsonism Relat Disord; 2006 Oct; 12(7):443-52. PubMed ID: 16798054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of Parkinson's disease.
    Shan DE; Wu HC; Chan LY; Liu KD
    Acta Neurol Taiwan; 2011 Mar; 20(1):65-72. PubMed ID: 21249581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
    Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
    Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness and Dynamic Efficiency: Does the Solution Lie Within?
    Refoios Camejo R; Miraldo M; Rutten F
    Value Health; 2017 Feb; 20(2):240-243. PubMed ID: 28237202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of occupational therapy in Parkinson's disease: A randomized controlled trial.
    Sturkenboom IH; Hendriks JC; Graff MJ; Adang EM; Munneke M; Nijhuis-van der Sanden MW; Bloem BR
    Mov Disord; 2015 Jul; 30(8):1059-67. PubMed ID: 25854809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites.
    Stroupe KT; Weaver FM; Cao L; Ippolito D; Barton BR; Burnett-Zeigler IE; Holloway RG; Vickrey BG; Simuni T; Follett KA
    Mov Disord; 2014 Nov; 29(13):1666-74. PubMed ID: 25220042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease.
    Postma MJ; Boersma C
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):1-4. PubMed ID: 22142151
    [No Abstract]   [Full Text] [Related]  

  • 16. The cost of a QALY.
    Kirkdale R; Krell J; Brown CO; Tuthill M; Waxman J
    QJM; 2010 Sep; 103(9):715-20. PubMed ID: 20519275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 19. Hidden Treasures and Secret Pitfalls: Application of the Capability Approach to ParkinsonNet.
    Canoy M; Faber MJ; Munneke M; Oortwijn W; Nijkrake MJ; Bloem BR
    J Parkinsons Dis; 2015; 5(3):575-80. PubMed ID: 26406138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effect pharmacological studies of Parkinson's disease].
    Chikina ES; Belousov IuB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(11):68-72. PubMed ID: 16329642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.